Eisai Says Alzheimer’s Care Shifts Earlier With 3 Years of Anti-Amyloid Data
Updated
Updated · STAT · Jul 12
Eisai Says Alzheimer’s Care Shifts Earlier With 3 Years of Anti-Amyloid Data
2 articles · Updated · STAT · Jul 12
Summary
Earlier intervention is becoming feasible in Alzheimer’s disease as blood-based biomarkers, neuroimaging and anti-amyloid therapies converge, Eisai’s Lynn Kramer said.
Three years of real-world anti-amyloid evidence from the LEADER study, presented at AAIC 2026, supports a move from symptom-based care toward biomarker-defined diagnosis and stage-specific treatment.
Blood-based biomarkers such as plasma p-tau and amyloid ratios could widen access because they are less burdensome than CSF testing or amyloid PET and are increasingly showing comparable reliability.
Late diagnosis still persists because stigma, misconceptions about aging, and complex care pathways delay evaluation until symptoms disrupt daily life and neuronal damage is already significant.
Eisai said programs such as the Davos Alzheimer’s Collaborative Brain Health Navigator aim to speed referrals and connect diagnosis with follow-up as care becomes more proactive and personalized.
With new blood tests simplifying diagnosis, will primary care doctors soon screen for Alzheimer's as routinely as for cholesterol?
As amyloid drugs show only modest benefits, are therapies targeting tau and inflammation the next real hope for halting Alzheimer's?
Four Years of Lecanemab: Sustained Efficacy, Early Intervention, and the New Era of Alzheimer’s Disease Treatment
Overview
Alzheimer's treatment is changing rapidly, thanks to strong four-year data from lecanemab studies. This evidence shows that starting lecanemab early leads to better and longer-lasting results in slowing memory and functional decline. The Clarity AD study's long-term findings, presented at a major 2026 conference, confirm that lecanemab is both effective and safe over four years of continuous use. These results are driving a new approach that focuses on early intervention, giving hope for improved quality of life for patients and their families.